A federal judge on Thursday said plaintiffs suing Mylan NV for engaging in an allegedly unlawful scheme to squelch competition and sharply raise prices for its EpiPen allergy treatment can proceed as a class.
To read the full story on WestlawNext Practitioner Insights, click here
Comments